Qual é o preço para Elicio Therapeutics, Inc. (ELTX)

O preço para Elicio Therapeutics, Inc. (ELTX) é $3.09

Qual é a capitalização de mercado para Elicio Therapeutics, Inc. (ELTX)

A capitalização de mercado para Elicio Therapeutics, Inc. (ELTX) é $58.82M

Histórico de Preços de Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Ano	Desempenho
2026 (TTM)	9.17%
2025	59.27%
2024	-21.55%
2023	0.00%

Ano

Desempenho

2026 (TTM)

9.17%

2025

59.27%

2024

-21.55%

2023

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$550.26	38.44%	US
Argenx SE ARGX.US	$1.05K	58.16%	NL
Moderna, Inc. MRNA.US	$148.90	467.89%	US
CSL Limited CSL.AX	$118.70	-18.24%	AU
Lonza Group AG LONN.SW	$770.19	9.84%	CH

Empresa

Preço da ação

Variação 1a%

País